A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Incidence and severity of AEs and SAEs by treatment group, including Safety findings, Laboratory tests, Vital signs and, ECG findings qualifying and reported as AEs.

Time frame: From First treatment to end of study (up to 63 months approximately)

Change from Baseline in Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)

The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care.

Time frame: Baseline over time until Week 72

Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog14)

The ADAS-Cog is is a 14-item clinical assessment tool to measure cognition. The ADAS-Cog14 score ranges between 0 and 90, with higher scores indicating worse cognitive performance

Time frame: Baseline over time until Week 72

Change from Baseline in instrumental activities of daily living (iADL) on the Alzheimers Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale

The ADCS-ADL is a 23-item study partner scale designed to assess the ability of patients with AD to carry out basic activities of daily living (bADLs) and instrumental activities of daily living (iADLs). For each item, the study partner is asked whether the participant attempted the activity in the 4 preceding weeks. Where 'yes' is the answer, the study partner is asked to rate the patient's level of performance according to a set of descriptors tailored to that activity. Scores on iADL sub-scale range between 0 and 59, with lower scores reflecting greater disease severity